Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Phase III Results Show Moderna Could Challenge In Blockbuster RSV Vaccine Market

First Data Cut Shows 83% Efficacy Against Infection

Executive Summary

Moderna has moved fast to catch up with GSK and Pfizer, but will still be up to a year behind in reaching the market in the burgeoning RSV market.

You may also be interested in...



GSK Exceeded Expectations In 2022, Now Looking For Edge Over Pfizer In RSV Battle

Having outperformed in 2022, GSK is gearing up for key regulatory and market access decisions on its RSV vaccine, but is confident it holds superior data compared with rival Pfizer.

Moderna Chalks Up Industry Milestone With mRNA Cancer Vaccine Efficacy Success

Phase IIb KEYNOTE-942 study shows mRNA-4157/V940 paired with Keytruda reduces risk of recurrence and death in post-surgical melanoma patients compared with Keytruda alone.

RSV Market Shake Up Starts As Sanofi And AZ’s Beyfortus Wins First Approval

The firms’ monoclonal antibody has received the EU green light just months after a positive CHMP opinion with observers projecting billions in peak sales as it becomes the first new RSV prophylactic in decades.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel